Sippert Emilia Ângela, Visentainer Jeane Eliete Laguila, Alves Hugo Vicentin, Rodrigues Camila, Gilli Simone Cristina Olenscki, Addas-Carvalho Marcelo, Saad Sara Teresinha Ollala, Costa Fernando Ferreira, Castilho Lilian
Hematology and Hemotherapy Center, State University of Campinas, UNICAMP, Campinas, São Paulo, Brazil.
Basic Health Sciences Department, State University of Maringa, Maringá, Paraná, Brazil.
Transfusion. 2017 Feb;57(2):379-389. doi: 10.1111/trf.13920. Epub 2016 Nov 21.
The reason for the difference in susceptibility to red blood cell (RBC) alloimmunization among patients with sickle cell disease (SCD) is not clearly understood and is probably the result of multiple factors. Our hypothesis is that genetic polymorphisms are associated with RBC alloimmunization.
We investigated the possible association of susceptibility to RBC alloimmunization with polymorphisms of HLA and cytokines genes in 161 SCD patients prior exposed to RBC transfusion. Cytokine gene polymorphisms were analyzed by polymerase chain reaction (PCR) and TaqMan assays. HLA Class I genotyping was performed using PCR-specific sequence of oligonucleotides. Polymorphism frequencies were compared using the Fisher's exact test.
Our results revealed increased percentage of the A allele and the GA genotype of the TNFA -308G/A cytokine among alloimmunized patients when compared to nonalloimmunized patients (A allele, 16.4% vs. 6.8%, p = 0.004; GA genotype, 32.8% vs. 11.7%, p = 0.0021). In addition, the IL1B -511T allele and the IL1B -511TT and CT genotype frequencies were overrepresented among alloimmunized patients (T allele, 53.0% vs. 37.5%, p = 0.0085; CT + TT genotypes, 81.82% vs. 60.87%, p = 0.0071). In relation to HLA Class I, we found a higher frequency of HLA-DRB1*15 among patients alloimmunized to Rh antigens when compared to nonalloimmunized patients (15.63% vs. 6.98%, p = 0.044).
Brazilian SCD patients with the TNFA, IL1B, and HLA-DRB1 gene polymorphisms were at increased risk of becoming alloimmunized by RBC transfusions. These findings may contribute to the development of future therapeutic strategies for patients with SCD with higher susceptibility of alloimmunization.
镰状细胞病(SCD)患者对红细胞(RBC)同种免疫的易感性差异原因尚不清楚,可能是多种因素导致的。我们的假设是基因多态性与RBC同种免疫有关。
我们调查了161例既往接受过RBC输血的SCD患者中,RBC同种免疫易感性与HLA和细胞因子基因多态性之间的可能关联。细胞因子基因多态性通过聚合酶链反应(PCR)和TaqMan分析进行检测。HLA I类基因分型采用PCR特异性寡核苷酸序列进行。使用Fisher精确检验比较多态性频率。
我们的结果显示,与未发生同种免疫的患者相比,发生同种免疫的患者中TNFA -308G/A细胞因子的A等位基因和GA基因型百分比增加(A等位基因,16.4%对6.8%,p = 0.004;GA基因型,32.8%对11.7%,p = 0.0021)。此外,IL1B -511T等位基因以及IL1B -511TT和CT基因型频率在发生同种免疫的患者中过高(T等位基因,53.0%对37.5%,p = 0.0085;CT + TT基因型,81.82%对60.87%,p = 0.0071)。关于HLA I类,我们发现与未发生同种免疫的患者相比,对Rh抗原发生同种免疫的患者中HLA-DRB1*15的频率更高(15.63%对6.98%,p = 0.044)。
具有TNFA、IL1B和HLA-DRB1基因多态性的巴西SCD患者因RBC输血而发生同种免疫的风险增加。这些发现可能有助于为同种免疫易感性较高的SCD患者制定未来的治疗策略。